toripalimab
junshi biosciences,coherus
['neotorch', 'toripalimab', 'nsclc', 'sclc', 'lcsm,(-blcsm)']
neotorch study #asco23: pts with stage ii-iiia nsclc were randomized to neoadj chemo (x3 cycles) toripalimab followed by a cycle of chemo toripalimab efs (hr 0.40), mpr (48.5% vs 8.4%) and pcr (24.8% vs 1%) with toripalimab #lcsm 
Assistant Prof | Thoracic Oncology & Phase-I @karmanoscancer | EIC @BTFCancerNews | Previously @MayoCancerCare @gundersenhealth @JeffHealthAb | Tweets my own